Thromboembolism is a fatal complication in hip surgery.A variety of pharmacological measures have been proposed for prophylaxis.The purpose of the present study was to compare the rate of bleeding complications in a group of patient who received intravenous heparin therapy with the rate in a control group who received no prophylaxis. 25,000 units of heparin were used by continuous infusion postoperatively.We used ACT (activated clotting time) as a parameter for heparin.ACT is a moderately sensitive screening test for deficiencies in the intrinsic and common pathways of the clotting factor cascade.It is an estimate of the partial thromboplastin time (PPT).ACT was maintained at roughly 200 seconds, almost twice the normal value.Warf arin was begun after the infusion of heparin.The mean transfusion requirement and the mean amount of wound drainage showed no significant differences.There were no instances of wound hematoma and intraocular, retroperitoneal, or intracranial bleeding. We conclude that the use of ACT, enables safe anticoagulant treatment safely.
We report the clinical and radiographic results of Chiari pelvic osteotomy in 9 hips. The average age of patients at the fine of surgery was 37.6years and they were followed up for an average of 79 months. We utilized the Japanese Orthopedic Association (JOA) score for clinical evaluation and CE angle, Sharp angle, AHI. The mean postoperative JOA score of patients with Chiari pelvic osteotomy was 81 points. One patients achieved a poor results which was due to an incorrect preoperative indication. We found that valgus osteotomy with Chiari pelvic osteotomy was effective even for treating advanced hip stages.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.